NASDAQ:PRCT PROCEPT BioRobotics (PRCT) Stock Forecast, Price & News $31.75 -0.75 (-2.31%) (As of 12:02 PM ET) Add Compare Share Share Today's Range$30.94▼$32.2850-Day Range$26.64▼$37.0252-Week Range$25.29▼$52.40Volume117,856 shsAverage Volume366,692 shsMarket Capitalization$1.43 billionP/E RatioN/ADividend YieldN/APrice Target$46.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media PROCEPT BioRobotics MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside48.9% Upside$46.83 Price TargetShort InterestHealthy5.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.69Based on 10 Articles This WeekInsider TradingSelling Shares$1.25 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.20) to ($1.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector290th out of 980 stocksSurgical & Medical Instruments Industry25th out of 97 stocks 3.4 Analyst's Opinion Consensus RatingPROCEPT BioRobotics has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $46.83, PROCEPT BioRobotics has a forecasted upside of 48.9% from its current price of $31.45.Amount of Analyst CoveragePROCEPT BioRobotics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.16% of the float of PROCEPT BioRobotics has been sold short.Short Interest Ratio / Days to CoverPROCEPT BioRobotics has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in PROCEPT BioRobotics has recently decreased by 15.06%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPROCEPT BioRobotics does not currently pay a dividend.Dividend GrowthPROCEPT BioRobotics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRCT. Previous Next 3.2 News and Social Media Coverage News SentimentPROCEPT BioRobotics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for PROCEPT BioRobotics this week, compared to 2 articles on an average week.Search Interest5 people have searched for PRCT on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PROCEPT BioRobotics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,245,196.00 in company stock.Percentage Held by Insiders19.60% of the stock of PROCEPT BioRobotics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.40% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($2.20) to ($1.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PROCEPT BioRobotics is -14.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PROCEPT BioRobotics is -14.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPROCEPT BioRobotics has a P/B Ratio of 7.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About PROCEPT BioRobotics (NASDAQ:PRCT) StockPROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.Read More Receive PRCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter. Email Address PRCT Stock News HeadlinesJune 3, 2023 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Down 6.2%June 2, 2023 | americanbankingnews.comAnalysts Offer Predictions for PROCEPT BioRobotics Co.'s Q2 2023 Earnings (NASDAQ:PRCT)June 5, 2023 | Edge On The Street (Ad)AI industry Is Exploding! New Breakthrough Expected this SummerBill Gates says the AI Era has begun. Every tech company is looking to integrate artificial intelligence. A young company holds the secret to the next biggest AI advancement.June 2, 2023 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) Earns Outperform Rating from Analysts at William BlairMay 31, 2023 | msn.comWilliam Blair Initiates Coverage of Procept BioRobotics (PRCT) with Outperform RecommendationMay 30, 2023 | seekingalpha.comProcept BioRobotics: Adding For 2023 ReboundMay 30, 2023 | americanbankingnews.comPROCEPT BioRobotics Co. (NASDAQ:PRCT) Short Interest Down 15.1% in MayMay 26, 2023 | americanbankingnews.comReviewing Intelligent Bio Solutions (NASDAQ:INBS) and PROCEPT BioRobotics (NASDAQ:PRCT)June 5, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. May 19, 2023 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) Shares Down 4.7% May 18, 2023 | americanbankingnews.comPROCEPT BioRobotics Co. (NASDAQ:PRCT) Receives $46.83 Consensus Target Price from AnalystsMay 17, 2023 | finance.yahoo.comPositive week for PROCEPT BioRobotics Corporation (NASDAQ:PRCT) institutional investors who lost 17% over the past yearMay 12, 2023 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) & Sensus Healthcare (NASDAQ:SRTS) Head to Head ReviewMay 5, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for PROCEPT BioRobotics Co. Raised by KeyCorp (NASDAQ:PRCT)May 1, 2023 | msn.comKeybanc Maintains Procept BioRobotics (PRCT) Overweight RecommendationMay 1, 2023 | markets.businessinsider.comKeyBanc Keeps Their Buy Rating on PROCEPT BioRobotics (PRCT)May 1, 2023 | markets.businessinsider.comPROCEPT BioRobotics (PRCT) Gets a Buy from B.Riley FinancialApril 30, 2023 | seekingalpha.comPROCEPT BioRobotics Corporation (PRCT) Q1 2023 Earnings Call TranscriptApril 29, 2023 | msn.comTruist Securities Maintains Procept BioRobotics (PRCT) Buy RecommendationApril 29, 2023 | msn.comB of A Securities Maintains Procept BioRobotics (PRCT) Buy RecommendationApril 29, 2023 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) Reaches New 52-Week Low After Earnings MissApril 29, 2023 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) Given New $44.00 Price Target at Bank of AmericaApril 29, 2023 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) Given New $49.00 Price Target at Truist FinancialApril 29, 2023 | americanbankingnews.comPROCEPT BioRobotics Target of Unusually High Options Trading (NASDAQ:PRCT)April 28, 2023 | finance.yahoo.comFive-Year Data from the WATER II Study Demonstrate Aquablation Therapy Delivers Significant Durable Improvement of Benign Prostatic Hyperplasia Symptoms while Preserving Sexual Function in Men with Large ProstatesApril 27, 2023 | finance.yahoo.comPROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue EstimatesApril 27, 2023 | finance.yahoo.comWhy Shares of Procept Biorobotics Were Slumping ThursdaySee More Headlines PRCT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRCT Company Calendar Last Earnings4/27/2023Today6/05/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRCT CUSIPN/A CIK1588978 Webwww.procept-biorobotics.com Phone650-232-7200FaxN/AEmployees234Year FoundedN/APrice Target and Rating Average Stock Price Forecast$46.83 High Stock Price Forecast$53.00 Low Stock Price Forecast$43.00 Forecasted Upside/Downside+44.1%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,150,000.00 Net Margins-115.53% Pretax Margin-115.53% Return on Equity-45.87% Return on Assets-30.99% Debt Debt-to-Equity Ratio0.31 Current Ratio7.56 Quick Ratio6.36 Sales & Book Value Annual Sales$75.01 million Price / Sales19.52 Cash FlowN/A Price / Cash FlowN/A Book Value$3.84 per share Price / Book8.46Miscellaneous Outstanding Shares45,050,000Free Float36,219,000Market Cap$1.46 billion OptionableNot Optionable Beta0.57 Key ExecutivesDr. Reza Zadno Ph.D. (Age 68)Pres, CEO & Director Comp: $759.5kMr. Kevin Waters (Age 46)Exec. VP & CFO Comp: $543.38kMr. Hisham Shiblaq (Age 47)Exec. VP & Chief Commercial Officer Comp: $507.5kMr. Mohan F. Sancheti (Age 59)Sr. VP of Operations Ms. Alaleh Nouri (Age 44)EVP, Chief Legal Officer & Corp. Sec. Ms. Minni VittalSr. VP & Chief People OfficerMr. Bijesh ChandranSr. VP of Regulatory Affairs & Quality AssuranceMr. Barry TemplinSr. VP of Clinical & Medical AffairsDr. Thomas J. Yorkey Ph.D. (Age 61)Sr. VP of R&D More ExecutivesKey CompetitorsLeMaitre VascularNASDAQ:LMATParagon 28NYSE:FNAEmbectaNASDAQ:EMBCTreace Medical ConceptsNASDAQ:TMCISilk Road MedicalNASDAQ:SILKView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Bought 27,235 shares on 5/22/2023Ownership: 0.060%JPMorgan Chase & Co.Bought 51,679 shares on 5/18/2023Ownership: 0.180%New York State Common Retirement FundSold 5,907 shares on 5/18/2023Ownership: 0.030%Squarepoint Ops LLCBought 25,980 shares on 5/16/2023Ownership: 0.117%Brookfield Corp ON Sold 11,319 shares on 5/16/2023Ownership: 0.068%View All Insider TransactionsView All Institutional Transactions PRCT Stock - Frequently Asked Questions Should I buy or sell PROCEPT BioRobotics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRCT shares. View PRCT analyst ratings or view top-rated stocks. What is PROCEPT BioRobotics' stock price forecast for 2023? 7 Wall Street research analysts have issued 12 month target prices for PROCEPT BioRobotics' stock. Their PRCT share price forecasts range from $43.00 to $53.00. On average, they anticipate the company's stock price to reach $46.83 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for PRCT or view top-rated stocks among Wall Street analysts. How have PRCT shares performed in 2023? PROCEPT BioRobotics' stock was trading at $41.54 on January 1st, 2023. Since then, PRCT stock has decreased by 21.8% and is now trading at $32.50. View the best growth stocks for 2023 here. Are investors shorting PROCEPT BioRobotics? PROCEPT BioRobotics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 2,200,000 shares, a decline of 15.1% from the April 30th total of 2,590,000 shares. Based on an average daily volume of 403,200 shares, the days-to-cover ratio is currently 5.5 days. Approximately 5.2% of the shares of the company are sold short. View PROCEPT BioRobotics' Short Interest. When is PROCEPT BioRobotics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our PRCT earnings forecast. How were PROCEPT BioRobotics' earnings last quarter? PROCEPT BioRobotics Co. (NASDAQ:PRCT) posted its earnings results on Thursday, April, 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by $0.04. The business earned $24.40 million during the quarter, compared to analysts' expectations of $24.32 million. PROCEPT BioRobotics had a negative trailing twelve-month return on equity of 45.87% and a negative net margin of 115.53%. PROCEPT BioRobotics's quarterly revenue was up 71.8% on a year-over-year basis. During the same period last year, the company posted ($0.39) earnings per share. What ETFs hold PROCEPT BioRobotics' stock? ETFs with the largest weight of PROCEPT BioRobotics (NASDAQ:PRCT) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), ALPS Disruptive Technologies ETF (DTEC), Global X Robotics & Artificial Intelligence Thematic ETF (BOTZ), Principal Healthcare Innovators ETF (BTEC), First Trust Small Cap Growth AlphaDEX Fund (FYC), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), Invesco DWA SmallCap Momentum ETF (DWAS) and What guidance has PROCEPT BioRobotics issued on next quarter's earnings? PROCEPT BioRobotics issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $128.00 million-$128.00 million, compared to the consensus revenue estimate of $126.71 million. When did PROCEPT BioRobotics IPO? (PRCT) raised $126 million in an initial public offering on Wednesday, September 15th 2021. The company issued 5,500,000 shares at $22.00-$24.00 per share. What is PROCEPT BioRobotics' stock symbol? PROCEPT BioRobotics trades on the NASDAQ under the ticker symbol "PRCT." Who are PROCEPT BioRobotics' major shareholders? PROCEPT BioRobotics' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.94%), BlackRock Inc. (4.21%), Price T Rowe Associates Inc. MD (2.98%), State Street Corp (1.77%), Geode Capital Management LLC (1.32%) and Frank Rimerman Advisors LLC (1.01%). Insiders that own company stock include Alaleh Nouri, Global Investors Lp Viking, Hisham Shiblaq, Kevin Waters, Morgan Colby Wood, Reza Zadno and Thomas M Krummel. View institutional ownership trends. How do I buy shares of PROCEPT BioRobotics? Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is PROCEPT BioRobotics' stock price today? One share of PRCT stock can currently be purchased for approximately $32.50. How much money does PROCEPT BioRobotics make? PROCEPT BioRobotics (NASDAQ:PRCT) has a market capitalization of $1.46 billion and generates $75.01 million in revenue each year. The company earns $-87,150,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. How many employees does PROCEPT BioRobotics have? The company employs 234 workers across the globe. How can I contact PROCEPT BioRobotics? PROCEPT BioRobotics' mailing address is 900 ISLAND DRIVE, REDWOOD CITY CA, 94065. The official website for the company is www.procept-biorobotics.com. The company can be reached via phone at 650-232-7200 or via email at ir@procept-biorobotics.com. This page (NASDAQ:PRCT) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.